Vautia Therapeutics ApS
CVR 45465578 · Private limited company (ApS) · Active · Medium risk
Vautia Therapeutics ApS is a Private limited company (ApS), founded on , based in København K. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.8% over the next 12 months, which is 1.3 times the average for Danish companies. 1 annual report has been published. The latest annual report (31 Dec 2025) shows equity of DKK 23k and a net result of DKK -17k. CEO: Mohammad Sohail Asghar.
Bankruptcy risk for Vautia Therapeutics ApS
1.3 × the average (1.41%) · higher risk than 81% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 45465578
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (1 years)
- Address
- Frederiksgade 11, st. th
1265 København K - Municipality
- København
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 40k
- Auditor
- Kreston CMStatsautoriseret revisionsinteressentskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 1 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 62.0% |
| Current ratio | 263% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 53 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|---|
| Gross profit | DKK -17k |
| Net profit | DKK -17k |
| Equity | DKK 23k |
| Total assets | DKK 37k |
| Cash | DKK 37k |
| Short-term debt | DKK 14k |
| Avg. employees | 0 |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Kreston CMStatsautoriseret revisionsinteressentskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 11 Mar 2025 – 31 Dec 2025 | 166 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Mohammad Sohail Asghar | Current | |
| Owner (50%) | MSA ApS | Current | |
| Owner (50%) | Schøier Holding ApS | Current | |
| Founder | MSA ApS | Current | |
| Founder | Schøier Holding ApS | Current |
The CEOs' other companies
Mohammad Sohail Asghar – 5 other companies
- Frederiksstaden Pharma ApS Active
- HB MEDICAL SCANDINAVIA A/S Fusioneret
- MSA ApS Active
- SAIM Medical ApS Active
- XGX Pharma ApS Active
Address history (0 moves)
| Frederiksgade 11, st. th, 1265 København K |
Other companies at the same address
- AKTIESELSKABET UNIVERSAL REPRO SERVICE Bankrupt
- SFPN INVEST ApS Bankrupt
- A69 ApS Active
- ACORN SPV ApS Active
- AxCap Founders GP ApS Active
- AxCap GP ApS Active
- AxCap Management 1 ApS Active
- BALDERSGADE 48 ApS Active
- BRUNDE STORCENTER ApS Fusioneret
- Bellidavej 20 Holding ApS Active
- Birch SPV ApS Opløst
- CARL BERNHARDSVEJ NR. 9-11 ApS Active
- CD Projects ApS Active
- CEDAR ApS Opløst
- Charlie Tango Management ApS Active
- D14 ApS Active
- DIG Global A/S Active
- DIG Global GP ApS Active
- DIG Investment Management Denmark A/S Active
- Dragon SPV ApS Opløst
- EJENDOMSSELSKABET AF 19.10.1953 ApS Active
- ELM SPV ApS Active
- Ejendomsselskabet Frederiksgade 11 ApS Active
- Entreprenørselskabet af 3/2 2016 ApS Fusioneret
- F7 ApS Active
Similar companies in København
- H. LUNDBECK A/S Valby
- GUNNAR KJEMS ApS København K
- Tetrapharm Therapeutics ApS København S
- Tetrapharm Bioengineering ApS København S
- Luvalis Pharma ApS Vanløse
- NeuroVersis Therapeutics ApS København K
- QuantumCell ApS København K
- Corxel Pharmaceuticals Denmark ApS København V
- Dispersome IP ApS København Ø
- Maddox Pharma Swiss ApS København S
- Gefjon Pharma ApS København N
- Linker Pharmaceuticals ApS København K
Questions and answers about Vautia Therapeutics ApS
Has Vautia Therapeutics ApS gone bankrupt?
No, Vautia Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Vautia Therapeutics ApS?
Our model estimates a bankruptcy risk of 1.8% over the next 12 months (medium risk), which is 1.3 times the average for Danish companies.
Who is the CEO of Vautia Therapeutics ApS?
Mohammad Sohail Asghar is the CEO of Vautia Therapeutics ApS.
Who is the auditor of Vautia Therapeutics ApS?
Vautia Therapeutics ApS most recently used Kreston CMStatsautoriseret revisionsinteressentskab.
When was Vautia Therapeutics ApS founded?
Vautia Therapeutics ApS was founded on 11 March 2025.
What is the equity of Vautia Therapeutics ApS?
Equity was DKK 23k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.